|
Distribution of clinicopathological parameters in 1,000 high-risk breast cancer patients |
||||
| Radiotherapy |
No radiotherapy |
χ2 |
||
|
|
||||
| All |
489 (49%) |
511 (51%) |
||
| Protocol |
Pre (DBCG82b) |
267 (54%) |
296 (58%) |
0.3 |
| Post (DBCG82c) |
222 (46%) |
215 (42%) |
||
| Tumour size (mm) |
<21 |
171 (35%) |
190 (37%) |
0.1 |
| 21 to 50 |
259 (53%) |
242 (47%) |
||
| >50 |
59 (12%) |
79 (15%) |
||
| Positive nodes |
None |
29 (6%) |
31 (6%) |
0.8 |
| 1 to 3 |
222 (46%) |
220 (43%) |
||
| >3 |
238 (49%) |
260 (51%) |
||
| Histopathology |
Ductal |
428 (88%) |
427 (84%) |
0.1 |
| Nonductal |
61 (12%) |
84 (16%) |
||
| Malignancy grade (ductal only) |
Grade 1 |
98 (23%) |
97 (23%) |
0.7 |
| Grade 2 |
213 (50%) |
223 (52%) |
||
| Grade 3 |
117 (27%) |
107 (25%) |
||
| ER |
Positive |
327 (67%) |
344 (67%) |
0.4 |
| Negative |
160 (33%) |
167 (33%) |
||
| Unknown |
2 (0%) |
0 (0%) |
||
| PgR |
Positive |
283 (58%) |
313 (61%) |
0.3 |
| Negative |
205 (42%) |
198 (39%) |
||
| Unknown |
1 (0%) |
0 (0%) |
||
| HER2 |
Negative |
376 (77%) |
404 (79%) |
0.6 |
| Positive |
110 (22%) |
106 (21%) |
||
| Unknown |
3 (1%) |
1 (0%) |
||
| CA IX |
Negative |
386 (79%) |
408 (80%) |
0.3 |
| Positive |
80 (16%) |
71 (14%) |
||
| Unknown |
23 (5%) |
32 (6%) |
||
|
Shown is the distribution of various clinicopathological parameters, including oestrogen receptor (ER), progesterone receptor (PgR), human epideraml growth factor receptor (HER)2 and carbonic anhydrase (CA) IX among 1,000 high-risk breast cancer patients randomly assigned to receive or not receive postmastectomy radiotherapy. | ||||
Kyndi et al. Breast Cancer Research 2008 10:R24 doi:10.1186/bcr1981 |
||||